The global colorectal cancer screening market size was estimated to be USD 14.75 billion in 2023 and is expected to reach at USD 26.53 billion by 2034 with a CAGR of 5.48% during the forecast period 2024-2034. Rising emphasis on developing & commercializing technologically advanced products for efficient screening, increasing incidence of colorectal cancer, growing awareness regarding the importance of early testing & treatment of the disease, surge in approvals for these screening tests, the implementation of government programs to control its side effects, and a growing focus among the major companies on the introduction of cutting-edge and novel items are some of the key factors boosting the market growth.
A growing focus among the major companies on the introduction of cutting-edge and novel items is predicted to boost the market growth during the forecast period. Colorectal Cancer (CRC) is a type of cancer that develops in the colon or rectum, part of the digestive tract, as cancerous cells begin to grow. Often referred to as bowel cancer, CRC screening involves identifying the disease in individuals who show no symptoms but are at a high risk of developing the condition, typically aged 45 and above. The growing incidence of CRC underscores the importance of screening for early diagnosis and treatment. For instance, in May 2022, Guardant Health has introduced Shield, a blood-based test designed for the early detection of colorectal cancer in adults aged 45 and older. This test, which involves a blood draw, is intended for individuals who are not in compliance with recommended screening guidelines, display no symptoms, and are at an average risk for colorectal cancer.
By type, colonoscopy was the highest revenue-grossing segment in the global colorectal cancer screening market in 2023 owing to the procedure exhibits a high level of accuracy, coinciding with a rising incidence of colorectal cancer, ongoing technological advancements, and an increasing number of product launches. For instance, in August 2022, India Medtronic Private Limited has unveiled a groundbreaking computer-aided polyp detection system, the GI Genius intelligent endoscopy module, powered by artificial intelligence (AI). This innovative solution relies on deep learning algorithms and real-time data to empower physicians in the detection and treatment of colorectal cancer by providing enhanced visualization during colonoscopy. Additionally, stool-based is predicted to grow at fastest CAGR during the forecast period owing to the increasing government initiatives for colorectal cancer screening, along with the prompt results achieved through stool-based tests, rising adoption of FIT screening tests due to their simplicity & higher positivity rates compared to other stool-based tests.
By end-user, hospitals & clinics was the highest revenue-grossing segment in the global colorectal cancer screening market in 2023 owing to the substantial number of hospitals, rising volume of colorectal cancer (CRC) screening procedures conducted within hospital settings, and increasing regulatory approvals. For instance, in December 2022, Therascreen KRAS RGQ PCR Kit for colorectal cancer screening, manufactured by QIAGEN Manchester Ltd., was authorized by the FDA. Additionally, diagnostics imaging centers is predicted to grow at fastest CAGR during the forecast period owing to the growing trend in colorectal cancer screening through colonoscopies, accompanied by an increasing number of diagnostic centers that offer and conduct colonoscopy procedures.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing adoption of technologically advanced & high-cost tests, growing awareness of colorectal cancer, rising demand for screening procedures such as stool-based testing, the presence of government programs further contributes to this trend, and surge in research & development activities. For instance, in December 2022, Guardant Health, Inc., a company based in the United States, has announced positive results from the ECLIPSE study (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Episode). This study, which involved over 20,000 patients, was conducted to evaluate the performance of Guardant Health's blood test in detecting colorectal cancer (CRC) in average-risk adults. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising trend in enhancing & improving healthcare facilities, increasing incidence of colorectal cancer, individuals are becoming more conscious of achieving better treatment outcomes, surge in awareness regarding the disease, and growing collaborations within market players for the launch of new products. For instance, in May 2022, Prenetics and New Horizon Health established their strategic alliance to introduce ColoClear by Circle in China.
A growing focus among the major companies on the introduction of cutting-edge and novel items is predicted to boost the market growth during the forecast period. Colorectal Cancer (CRC) is a type of cancer that develops in the colon or rectum, part of the digestive tract, as cancerous cells begin to grow. Often referred to as bowel cancer, CRC screening involves identifying the disease in individuals who show no symptoms but are at a high risk of developing the condition, typically aged 45 and above. The growing incidence of CRC underscores the importance of screening for early diagnosis and treatment. For instance, in May 2022, Guardant Health has introduced Shield, a blood-based test designed for the early detection of colorectal cancer in adults aged 45 and older. This test, which involves a blood draw, is intended for individuals who are not in compliance with recommended screening guidelines, display no symptoms, and are at an average risk for colorectal cancer.
By type, colonoscopy was the highest revenue-grossing segment in the global colorectal cancer screening market in 2023 owing to the procedure exhibits a high level of accuracy, coinciding with a rising incidence of colorectal cancer, ongoing technological advancements, and an increasing number of product launches. For instance, in August 2022, India Medtronic Private Limited has unveiled a groundbreaking computer-aided polyp detection system, the GI Genius intelligent endoscopy module, powered by artificial intelligence (AI). This innovative solution relies on deep learning algorithms and real-time data to empower physicians in the detection and treatment of colorectal cancer by providing enhanced visualization during colonoscopy. Additionally, stool-based is predicted to grow at fastest CAGR during the forecast period owing to the increasing government initiatives for colorectal cancer screening, along with the prompt results achieved through stool-based tests, rising adoption of FIT screening tests due to their simplicity & higher positivity rates compared to other stool-based tests.
By end-user, hospitals & clinics was the highest revenue-grossing segment in the global colorectal cancer screening market in 2023 owing to the substantial number of hospitals, rising volume of colorectal cancer (CRC) screening procedures conducted within hospital settings, and increasing regulatory approvals. For instance, in December 2022, Therascreen KRAS RGQ PCR Kit for colorectal cancer screening, manufactured by QIAGEN Manchester Ltd., was authorized by the FDA. Additionally, diagnostics imaging centers is predicted to grow at fastest CAGR during the forecast period owing to the growing trend in colorectal cancer screening through colonoscopies, accompanied by an increasing number of diagnostic centers that offer and conduct colonoscopy procedures.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing adoption of technologically advanced & high-cost tests, growing awareness of colorectal cancer, rising demand for screening procedures such as stool-based testing, the presence of government programs further contributes to this trend, and surge in research & development activities. For instance, in December 2022, Guardant Health, Inc., a company based in the United States, has announced positive results from the ECLIPSE study (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Episode). This study, which involved over 20,000 patients, was conducted to evaluate the performance of Guardant Health's blood test in detecting colorectal cancer (CRC) in average-risk adults. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising trend in enhancing & improving healthcare facilities, increasing incidence of colorectal cancer, individuals are becoming more conscious of achieving better treatment outcomes, surge in awareness regarding the disease, and growing collaborations within market players for the launch of new products. For instance, in May 2022, Prenetics and New Horizon Health established their strategic alliance to introduce ColoClear by Circle in China.
Segmentation: Colorectal Cancer Screening Market Report 2023 - 2034
Colorectal Cancer Screening Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Stool-Based
- Fecal Occult Blood Test (FOBT)
- Fecal Immunochemical Test (FIT)
- Stool-DNA Test
- Colonoscopy
- Others
Colorectal Cancer Screening Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Clinical Laboratories
- Hospitals & Clinics
- Diagnostic Imaging Centers
- Others
Colorectal Cancer Screening Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Colorectal Cancer Screening Market: Type Estimates & Trend Analysis
8. Colorectal Cancer Screening Market: End-user Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Colorectal Cancer Screening Market
11. Europe Global Colorectal Cancer Screening Market
12. Asia Pacific Global Colorectal Cancer Screening Market
13. Latin America Global Colorectal Cancer Screening Market
14. MEA Global Colorectal Cancer Screening Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- bioMérieux Inc.
- NOVIGENIX SA
- KARL STORZ SE & Co. KG
- Olympus Corporation
- Exact Sciences Corporation
- Epigenomics AG
- FUJIFILM Holdings America Corporation
- Clinical Genomics Technologies Pty Ltd.
- EIKEN CHEMICAL CO. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 14.75 Billion |
| Forecasted Market Value ( USD | $ 26.53 Billion |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
